Orciprenaline

Orciprenaline

Clinical data
AHFS/Drugs.com	monograph
MedlinePlus	a682084
Pregnancy category	AU: A US: C (Risk not ruled out)
Routes of administration	Inhalation / tablets
ATC code	R03AB03 (WHO) R03CB03 (WHO) R03CB53 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	3% if inhaled, 40% if taken orally
Metabolism	Gastrointestinal and hepatic
Elimination half-life	6 hours
Identifiers
IUPAC name (RS)-5-[1-hydroxy-2-(isopropylamino)ethyl]benzene-1,3-diol
CAS Number	586-06-1 Y
PubChem CID	4086
DrugBank	DB00816 N
ChemSpider	3944 Y
UNII	53QOG569E0
KEGG	D08300 Y
ChEBI	CHEBI:82719 N
ChEMBL	ChEMBL776 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C11H17NO3
Molar mass	211.258 g/mol
3D model (JSmol)	Interactive image
Solubility in water	9.7 mg/mL (20 °C)
SMILES Oc1cc(cc(O)c1)C(O)CNC(C)C
InChI InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-9(13)5-10(14)4-8/h3-5,7,11-15H,6H2,1-2H3 Y Key:LMOINURANNBYCM-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Orciprenaline
Articles
Most recent articles on Orciprenaline Most cited articles on Orciprenaline Review articles on Orciprenaline Articles on Orciprenaline in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Orciprenaline Images of Orciprenaline Photos of Orciprenaline Podcasts & MP3s on Orciprenaline Videos on Orciprenaline
Evidence Based Medicine
Cochrane Collaboration on Orciprenaline Bandolier on Orciprenaline TRIP on Orciprenaline
Clinical Trials
Ongoing Trials on Orciprenaline at Clinical Trials.gov Trial results on Orciprenaline Clinical Trials on Orciprenaline at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Orciprenaline NICE Guidance on Orciprenaline NHS PRODIGY Guidance FDA on Orciprenaline CDC on Orciprenaline
Books
Books on Orciprenaline
News
Orciprenaline in the news Be alerted to news on Orciprenaline News trends on Orciprenaline
Commentary
Blogs on Orciprenaline
Definitions
Definitions of Orciprenaline
Patient Resources / Community
Patient resources on Orciprenaline Discussion groups on Orciprenaline Patient Handouts on Orciprenaline Directions to Hospitals Treating Orciprenaline Risk calculators and risk factors for Orciprenaline
Healthcare Provider Resources
Symptoms of Orciprenaline Causes & Risk Factors for Orciprenaline Diagnostic studies for Orciprenaline Treatment of Orciprenaline
Continuing Medical Education (CME)
CME Programs on Orciprenaline
International
Orciprenaline en Espanol Orciprenaline en Francais
Business
Orciprenaline in the Marketplace Patents on Orciprenaline
Experimental / Informatics
List of terms related to Orciprenaline

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Orciprenaline (INN, also known as metaproterenol) is a bronchodilator used in the treatment of asthma. Orciprenaline is a moderately selective beta₂-adrenergic receptor agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on alpha-adrenergic receptors. The pharmacologic effects of beta adrenergic agonist drugs, such as orciprenaline, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of ATP to cAMP. Increased cAMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from many cells, especially from mast cells.

Possible side effects

• tremor
• nervousness
• dizziness
• weakness
• headache
• nausea
• tachycardia

Rare side effects that could be life-threatening

• increased difficulty breathing
• rapid or increased heart rate
• irregular heartbeat
• chest pain or discomfort

Brand names

• Alupent
• Metaprel